Dhingra Named Chairman of the Board of Directors at Lava Therapeutics
24 February 2021 - - Dutch early clinical-stage biotechnology company Lava Therapeutics B.V has appointed Dr. Kapil Dhingra as chairman of its board of directors, the company said.

Dhingra has more than 30 years of experience in oncology clinical research and drug development within the biotechnology and pharmaceutical industries, as a board member at several successful oncology biotechnology companies, and as a clinician at academic research centers.

Dhingra is a medical oncologist and a physician-scientist with a track record in academic research, patient care, and drug development.

He served as vice president, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development at Hoffmann-La Roche, during which he led numerous drug approvals, including Herceptin, Tarceva, and Avastin. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and company.

Dr. Dhingra has served as a faculty member at The University of Texas M.D. Anderson Cancer Center, Indiana University School of Medicine, and Memorial Sloan Kettering Cancer Center.

Dhingra is currently a member of the boards of directors of Black Diamond Therapeutics, Inc., Replimune, Inc., Five Prime Therapeutics, Inc., Autolus Therapeutics plc, and Median Technologies, and he has previously served on the boards of several biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, Epitherapeutics, Advanced Accelerator Applications, and Exosome Diagnostics. He is a member of the NCI Experimental Therapeutics Panel.

Dr. Dhingra founded KAPital Consulting, LLC in 2008, a company dedicated to helping biotechnology, pharmaceutical, and diagnostic companies realize the clinical and commercial advances in oncology.

He obtained his M.B.B.S. degree from the All India Institute of Medical Sciences in New Delhi, India.

He completed his residency in internal medicine at Lincoln Medical and Mental Health Center, New York Medical College and completed his fellowship in hematology and oncology at Emory University School of Medicine.

Lava Therapeutics is a developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its proprietary platform.

The company's innovative approach leverages bispecific antibodies to activate Vγ9Vδ2 T cells upon binding to membrane-expressed tumor associated antigens. Activated Vγ9Vδ2 T cells are engaged for direct, selective tumor cell killing.

The company's lead program, LAVA-051, is expected to enter a Phase 1/2a clinical study in hematologic malignancies in the first half of 2021. The company has established a highly experienced research and development team located in Utrecht, the Netherlands and Philadelphia, USA.